Antoine Saliba, MD
Hematology · Rochester, MNNPI 1780067314
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $52,300 with a category attached, or 95.6%. Pfizer accounts for 95.6% of it on its own, with 2 other manufacturers making up the rest.
Across 4 payments — averaging $13,075 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$50K
- Novartis$2K
- Daiichi Sankyo Inc.$650
What the payments were for
- Consulting fees$2,3004%
- Grants$50,00096%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 2 | $50,000 |
| Novartis | 1 | $1,650 |
| Daiichi Sankyo Inc. | 1 | $650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,300 in reported general payments places this provider in the 85th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 20 | $776,402 |
| JakafiRuxolitinib Phosphate | 58 | $737,483 |
| BosulifBosutinib | 11 | $134,981 |
| VenclextaVenetoclax | 27 | $82,022 |
| TasignaNilotinib Hcl | 13 | $66,788 |
| Fluconazole | 44 | $2,949 |
| Hydroxyurea | 63 | $2,263 |
| Cefdinir | 24 | $1,156 |
| Acyclovir | 77 | $949 |
| Levofloxacin | 32 | $479 |
| Rosuvastatin Calcium | 14 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerBosulif | $50,000 | $134,98111 claims |
| NovartisTasigna | $1,650 | $66,78813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 hematology providers in Minnesota.
Other hematology in Rochester
- Shaji KumarRochester$452K
- Yi LinRochester$365K
- David DingliRochester$299K
- Morie GertzRochester$261K
- Grzegorz NowakowskiRochester$235K
- Sameer ParikhRochester$151K
- Lindsey RoekerRochester$106K
- Mark LitzowRochester$99K
- Angela DispenzieriRochester$87K
- Prashant KapoorRochester$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.